First-in-human phase i study of fisogatinib (BLU-554) validates aberrant FGF19 signaling as a driver event in hepatocellular carcinoma
Journal
Cancer Discovery
Journal Volume
9
Journal Issue
12
Pages
1696-1707
Date Issued
2019
Author(s)
Kim R.D.
Sarker D.
Meyer T.
Yau T.
Macarulla T.
Park J.-W.
Choo S.P.
Hollebecque A.
Sung M.W.
Lim H.-Y.
Mazzaferro V.
Trojan J.
Zhu A.X.
Yoon J.-H.
Sharma S.
Chan S.L.
Faivre S.
Feun L.G.
Yen C.-J.
Dufour J.-F.
Palmer D.H.
Llovet J.M.
Manoogian M.
Tugnait M.
Stransky N.
Hagel M.
Kohl N.E.
Lengauer C.
Sherwin C.A.
Schmidt-Kittler O.
Hoeflich K.P.
Shi H.
Wolf B.B.
Kang Y.-K.
Publisher
American Association for Cancer Research Inc.
Type
journal article